Home > Healthcare > Pharmaceuticals > Finished Drug Form > Precision Medicine Market

Precision Medicine Market Share

Report ID: GMI671
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Precision Medicine Market Share

The precision medicine industry is characterized by intense competition, driven by ongoing innovation, strategic partnerships, and increasing demand for personalized healthcare solutions. With advancements in technology and a growing emphasis on precision medicine in clinical practice, the market is expected to continue expanding, presenting opportunities and challenges for both established and new players.

Precision Medicine Market Companies

Prominent players operating in the precision medicine industry include:

Abbott Laboratories, Inc.
Abbvie, Inc.
AstraZeneca plc
bioMerieux SA
Bristol-Myers Squibb Company
Cepheid (Danaher Corporation)
Eli Lilly & Company
F. Hoffmann-La Roche
GlaxoSmithKline plc
Laboratory Corporation of America Holdings (Covance Inc.)
Myriad Genetics, Inc.
Novartis AG
Pfizer, Inc.
QIAGEN N.V.
Quest Diagnostics
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vyant Bio, Inc. (Cancer Genetics, Inc.)

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global precision medicine industry size was USD 79.9 billion in 2023 and is projected to witness 7.6% CAGR between 2024 to 2032, driven by the increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and diabetes.

The therapeutic segment held 58.7% of the market share in 2023, owing to the growing focus on developing targeted therapies tailored to individual patient characteristics.

North America precision medicine market size will record 7.5% CAGR during 2024-2032, attributed to the well-established network of hospitals, research institutions, and diagnostic laboratories.

Abbott Laboratories, Inc., Abbvie, Inc., AstraZeneca plc, bioMerieux SA, Bristol-Myers Squibb Company, Cepheid (Danaher Corporation), Eli Lilly & Company, F. Hoffmann-La Roche, GlaxoSmithKline plc, Laboratory Corporation of America Holdings (Covance Inc.), Myriad Genetics, Inc. and Novartis AG